Genomic sequences of Streptococcus agalactiae with high-level gentamicin resistance, collected in the BSAC bacteraemia surveillance

The Journal of Antimicrobial Chemotherapy
Michel DoumithBSAC Resistance Surveillance Standing Committee

Abstract

Like other streptococci, Streptococcus agalactiae typically has intrinsic low-level aminoglycoside resistance. High-level gentamicin resistance was seen in 2 of 1125 isolates collected in the BSAC Bacteraemia Surveillance Programme between 2001 and 2014. These organisms, both isolated in 2014, were characterized. Identifications were by latex agglutination, MICs by BSAC agar dilution and sequencing by Illumina methodology. Gentamicin MICs were >1024 mg/L versus a species mode of 8 mg/L; both isolates also were unusually ciprofloxacin resistant with MICs of 64 mg/L versus a species mode of 1 mg/L. They were distinct by sequence, but both belonged to the ST19 clone, which occurs globally. Both had aac(6')-aph(2″), carried by different transposons, explaining their gentamicin resistance, and had gyrA[81:S-L];parC[79:S-Y], accounting for ciprofloxacin resistance. These are the first multiresistant S. agalactiae with the bifunctional AAC(6')-APH(2″) enzyme to be reported in the UK for >10 years. Despite belonging to the same clonal complex, the two isolates and their resistance transposons were distinct. Both retained full susceptibility to penicillin, but any penicillin/gentamicin synergy is likely to be lost.

References

Jan 1, 1984·Molecular & General Genetics : MGG·B R LyonR A Skurray
May 1, 1996·Antimicrobial Agents and Chemotherapy·T HoraudP Trieu-Cuot
Jul 4, 2002·The Journal of Antimicrobial Chemotherapy·H Liddy, R Holliman
Jun 28, 2005·Antimicrobial Agents and Chemotherapy·Adeline AchardRoland Leclercq
Oct 10, 2008·The Journal of Antimicrobial Chemotherapy·Rosy ReynoldsUNKNOWN BSAC Working Parties on Resistance Surveillance
Jul 13, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Theresa L LamagniElizabeth Sheridan
Jun 25, 2014·Antimicrobial Agents and Chemotherapy·A MontillaM Mollerach
Jul 15, 2015·The Journal of Antimicrobial Chemotherapy·Tomomi SekiYoshichika Arakawa

❮ Previous
Next ❯

Citations

Jul 19, 2019·Frontiers in Microbiology·Swaine L Chen
May 5, 2020·Critical Reviews in Microbiology·Katherine HayesLesley Cotter
Oct 31, 2020·Frontiers in Microbiology·Cinthia Alves-BarrocoPedro Viana Baptista
Aug 3, 2021·Frontiers in Microbiology·Cinthia Alves-BarrocoIlda Santos-Sanches

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.